Objective: As effects of glucocorticoids differ with respect to preparation, dose and duration, we hypothesized that a postnatal regimen of a low-dose, short-course betamethasone treatment had comparable efficacy and a better safety profile compared to the conventional high-dose, dexamethasone.
Introduction
Bronchopulmonary dysplasia (BPD) is one of the most challenging and persistent problems of modern neonatal medicine. Inflammatory processes beginning even in utero are important in the pathogenesis of BPD and have served as a rationale for the use of glucocorticoids (that is, dexamethasone) for neonates at high risk for this chronic condition. Postnatal dexamethasone produces significant improvement in pulmonary performance including compliance, functional residual capacity, inspired oxygen, minute ventilation plus a decreased incidence of BPD. 1, 2 However, use of dexamethasone in a conventional dosing regimen is also accompanied by adverse neurological outcomes, in particular hippocampal atrophy and cerebral palsy. [3] [4] [5] [6] In view of this, the American Academy of Pediatrics and the Canadian Academy of Pediatrics recommended that postnatal glucocorticoids not be routinely used in BPD. 7 In spite of these cautionary statements, postnatal glucocorticoids are still prescribed by about 40% of clinicians both in the United States and Europe. [8] [9] [10] [11] Therefore, for premature infants at risk of BPD, there is an important perceived need for a safe and efficacious steroid preparation that has an optimal dosing regimen.
Effects of glucocorticoids differ with respect to preparation, dose, duration and effects on the state of end-organ maturation. [12] [13] [14] Animal and tissue culture experiments show that low doses of glucocorticoids are neuroprotective whereas higher doses are neurodegenerative. 13, 15 At least 11 systemic reviews on postnatal systemic glucocorticoids published between 1992 and 2001 showed a greater risk of cerebral palsy among premature infants treated with dexamethasone, for long duration (21 to 42 days) using a high dose (>0.5 mg kg À1 per day).
7 Surprisingly, betamethasone is not commonly used as a postnatal glucocorticoid to treat BPD in premature infants even though there is compelling evidence of its safety and efficacy in postnatal outcomes following antenatal betamethasone use during pregnancy. First, antenatal betamethasone has been associated with a decreased risk of cystic periventricular leukomalacia (PVL) when compared to dexamethasone or the absence of glucocorticoid therapy. 16 Second, the penetration of dexamethasone into the central nervous system is higher compared to betamethasone because of higher lipid solubility and lower binding to serum proteins of dexamethasone compared to betamethasone. 17 Third, a single subcutaneous dose of 0.1 mg of betamethasone is 2-to 3-fold more potent than dexamethasone in accelerating fetal lung maturity without impairing fetal survival or weight gain. 18, 19 Fourth, betamethasone has been used in pregnancy for over 20 years with an unprecedented high level of safety and efficacy. 16 Fifth, importantly, recent studies in sheep and human infants have shown that intravenous betamethasone reduces cerebral blood flow, suggesting its vasoconstrictor effect. 20, 21 Thus, betamethasone might affect the incidence of intraventricular hemorrhage and PVL in extremely premature infants.
From this historical evidence, we reasoned that a low dose and short course of betamethasone would have similar efficacy but a better safety profile compared to the conventional use of dexamethasone (high dose, long course) and would provide a lower clinical risk to our patients who needed intervention. In January 2001 we revised our Division's clinical practice and adopted a betamethasone protocol. Subsequently, as part of a quality assurance review of outcomes for BPD, we compared the efficacy and incidence of adverse effects in premature infants who received our previous practice of a conventional regimen of dexamethasone, to the updated approach using a short-course, low-dose betamethasone protocol. We found that the short-course, low-dose betamethasone was equally efficacious, and had fewer undesirable side effects than a high dose, long course of dexamethasone.
Methods

Patient selection
The present report is a quality management review of our clinical practice for neonatal outcomes where we extracted medical records of 28 consecutively treated premature infants with dexamethasone who were admitted to the neonatal intensive care unit (NICU) between June 1999 and December 2000. This period was associated with various side effects of dexamethasone treatment including elevated blood pressure, hyperglycemia and failure to gain weight prompting our review of the literature described in the Introduction. Subsequently, we reviewed 20 consecutively treated premature infants with betamethasone from January 2001 to June 2002 using our clinically preferred betamethasone protocol. As we altered our routine practice of postnatal steroid treatment for evolving BPD and began using betamethasone instead of dexamethasone in January 2001, our strategic change in practice was and continues to be applied to all neonates who receive this therapy based on the safer pharmacological profile of a nearly identical drug. This quality improvement report is a case series that complies with all Health Insurance Portability and Accountability Act (HIPAA) of 1996 regulations for confidentiality.
Definition of failure to wean All newborns reviewed had a birth weight p1000 g and a gestational age of p29 weeks. In addition, they were mechanically ventilated on or beyond postnatal day 10 and received >40% fraction inspired oxygen (FiO 2 Fexpressed as per cent), and exhibited either an escalation in FiO 2 >10% (for example, from 40 to 50%) over 3 successive days or a lack of weaning over a 3-day period. The lack of weaning was defined as a failure to reduce FiO 2 by >10% (for example, from 50 to 40%) over 3 days while remaining within our predefined oxygen saturation targets. We excluded from analysis all infants who, before intervention had major congenital malformations, moderate to severe patent ductus arteriosus diagnosed by echocardiogram that did not close with indomethacin, renal compromise defined as a serum creatinine>2.0 mg per 100 ml, culture-proven sepsis, grade III or IV intraventricular hemorrhage or patients managed on highfrequency ventilation.
General medical management
All premature infants admitted to our NICU received our local standard of care based on decisions made by the attending neonatologists. During their admission, they received either enteral feeding, total parenteral nutrition or a combination; and their caloric intake was maintained X80 kcal kg À1 per day by the end of the first week using our feeding strategy. 22, 23 According to the NICU protocol, their weight, blood pressure, glucose, heart rate and ventilator settings including FiO 2 , peak inspiratory pressure (PIP), positive end-expiratory pressure (PEEP), mean airway pressure (MAP) as well as rate were recorded. Ventilator settings, arterial blood gases and other variables were recorded 7 days before, during and after the initiation of glucocorticoid therapy. Any changes in FiO 2 , PIP, MAP occurring after 3 and on 7 days of the initiation of glucocorticoid therapy were recorded as part of the data set.
Clinical definitions of efficacy
A clinically significant decrease in FiO 2 was defined as a reduction of at least 20%, a clinically significant decrease in PIP was defined as X4 cm H 2 O and a decrease in MAP was defined as a drop in MAP by 2 cm H 2 O or more for >24 h. Each of these benchmarks was compared at 72 h and 7 days after the initiation of dexamethasone or betamethasone treatment (Table 2 ). In addition, the oxygen index (OI) was calculated using the MAP as follows:
Ventilation strategy All infants received assist-control ventilation (Bird Ventilator; Palm Springs, CA, USA) using an 'optimal FRC strategy'. 24, 25 Our service has adopted a permissive hypercapnia approach, in which we use flow-loop dynamics to identify the PIP yielding the maximal compliance on assist-control ventilation with a termination sensitivity of 5%. Ventilator pressures (PIP or PEEP) are adjusted to achieve pHX7.25 when the base deficit is better than À5 mmol l À1 in spontaneously breathing neonates. When optimized pressures were identified, oximeter readings were maintained at 88 to 92% saturation by adjusting FiO 2 .
24,25
Perinatal and neonatal demographics Maternal characteristics of the patients enrolled were recorded. Gestational age was based on the date of last menstrual period and ultrasound performed before 20 weeks' gestation. Chorioamnionitis was defined as positive culture of amniotic fluid or as the following clinical signs: unexplained maternal temperature of more than 38 1C, elevated C-reactive protein, purulent amniotic fluid and uterine tenderness. Intrauterine growth retardation was defined as birth weight below the 10th percentile of the mean weight specific for the gestational age. Prenatal steroid use was defined as receipt of any maternal steroid within 7 days of the delivery of the baby.
Neonatal hospital outcomes including sepsis, PVL, number of ventilator days, number of days of oxygen, length of stay and BPD were recorded. Sepsis was defined as positive blood or spinal fluid culture for bacterial or fungal growth treated for 5 or more days with antibiotics. Periventricular leukomalacia was diagnosed when cranial ultrasonography revealed the presence of typical cystic lesions. BPD was diagnosed in infants who received supplemental oxygen to maintain oximeter reading 88 to 92% after 36 weeks' gestational age.
Steroid protocol
Infants having difficulty weaning from ventilatory support after postnatal day 10 in the standard epoch were treated with dexamethasone at a dose of 0.25 mg kg À1 per dose twice daily for 3 consecutive days and then tapered to 0.125 mg kg À1 per dose twice daily for the next 4 days intravenously (June 1999 to December 2000; total exposure: 2.5 mg kg À1 over 7 days). In contrast, infants in the revised epoch were treated with a lower cortisol-equivalent dose of glucocorticoids using betamethasone: 0.125 mg kg À1 per dose once daily for 3 consecutive days intramuscularly (January 2001 to December 2002; total exposure: 0.375 mg kg À1 over 3 days).
Statistical analysis
Data are presented as mean±standard error deviation (s.d.) followed by median and range to enable the greatest flexibility in interpretation. We compared demographic clinical characteristics of neonates for efficacy as well as potential adverse effects of betamethasone and dexamethasone treatment in premature infants. Comparison of continuous variables was done by Mann-Whitney U-test for nonparametric variables and t-test for parametric variables, whereas categorical variables were analyzed using Fisher's exact test. Multiple groups or observations were compared using analysis of variance (ANOVA). Statistical significance was attributed to P value less than 0.05.
Results
Characteristics of patients
Demographic characteristics of premature neonates included in this review are summarized in Table 1 . The mean gestational age and birth weight were comparable in betamethasone-and dexamethasone-treated patients. There were no statistical differences in other population characteristics between the two groups including race, percentage of infants with Apgar score less than 6 at 5 min, prenatal exposure to glucocorticoids, maternal chorioamnionitis or intrauterine growth retardation. Betamethasone or dexamethasone treatments were started on average at the same postnatal age (18 ± 2 vs 18 ± 6 days, respectively).
Therapeutic effects of betamethasone vs dexamethasone Oxygen requirements. Betamethasone or dexamethasone treatment significantly decreased FiO 2 on treatment days 4 to 7 and 8 to 14 compared to the day of initiation of drug intervention (P<0.05 each; repeated-measures ANOVA; Figure 1 ). However, the OI decreased significantly in only the dexamethasone groupX7 days after the initiation of treatment (P<0.05; Figure 1 ). In contrast, a decrease in FiO 2 by 20% or more at 72 h after the initiation of treatment was observed in 50% of the betamethasone cases and in just 35% of the neonates receiving dexamethasone ( Table 2 ). The percentage of newborns exhibiting a decrease in FiO 2 of 20% or more on day 7 compared to day 3 was the same for both groups. This suggested that premature neonates can be weaned to a lower oxygen level after as little as 3 days following the initiation of even low-dose glucocorticoids, consistent with a previous report. 26 Ventilator requirements. We also observed a reduction in ventilator support, including a lower PIP and MAP on days 3 and 7 after the initiation of therapy in both groups of neonates (Table 2 ); yet, there were no significant differences in the MAP on days 3 and 7 between the two treatment groups. Of note, in the betamethasone group, we observed a decrease in PIP of 4 cm H 2 O in 40 and 55% of infants at 72 h and again at 7 days after the initiation of treatment, respectively. In contrast, this magnitude of decrease in PIP was noted in just 7% of neonates in the dexamethasone group at either time points. The difference in size of reduction in PIP at both the 72 h and 7 days time points between the two treatment groups was statistically significant (P<0.05, both). Taken together, our ventilatory data suggest that betamethasone might be increasing lung compliance more effectively compared to dexamethasone, similar to benefits seen when comparing antenatal use. 16 The percentage of neonates extubated to continuous positive airway pressure, number of ventilation days and length of hospital stay were comparable between the two groups. Likewise, the number of days in oxygen, ventilator days, length of hospital stay and the incidence of BPD were similar in the two treatment groups, as we would predict. We do not have an untreated 'control' group but our overall incidence of BPD using our group's ventilation and glucocorticoid strategies 24 was 13% for infants born under 1 kg during this time period, which included 75% of concurrently treated extremely low birth weight (ELBW) patients who did not receive postnatal steroids. 25 Adverse effects of dexamethasone and betamethasone We observed (Table 3 ) a significantly greater weight gain (P<0.05; Figure 2 ; Table 3 ) and less hyperglycemia in patients receiving betamethasone compared to dexamethasone treatment (P<0.05; Figure 2 ), whereas the increase in systolic blood pressure was similar in the two groups. Infants receiving dexamethasone had a higher occurrence of sepsis (32 vs 10%) as well as more periventricular leukomalacia (7 vs 0%) compared to infants receiving betamethasone; however, these differences were not statistically significant. Overall, conventional dexamethasone therapy was attended by more short-term adverse effects than betamethasone treatment.
Discussion
This report describes postnatal use of betamethasone as glucocorticoid therapy in premature neonates at risk for BPD. We show that a short-course (3 days) and low-dose betamethasone intervention had comparable efficacy and apparently better shortterm safety profile as a conventional (7 days) dexamethasone regimen in the management of evolving BPD in extremely premature infants. Despite the use of a low dose (fivefold cortisol equivalent) and short course (3 days) of betamethasone treatment compared to conventional high dose (20-fold cortisol equivalent) and long course (7 days) of dexamethasone, the outcome measures including percent extubation, fall in FiO 2 and decrease in MAP showing average values of 7 days before, the first 3 days of treatment, days 3 through 7 of treatment and then for 7 days after intervention. There was a significant reduction in oxygenation index in the dexamethasone group only after 7 days but a significant reduction in FiO 2 that occurred after just 3 days of glucocorticoid treatment in both groups that persisted through day 14 of protocol (paired t-test used). *P<0.05.
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were similar in the two treatment groups. Notably, a decrease in PIP was significantly greater in infants treated with betamethasone than dexamethasone consistent with improved lung compliance. This effect could be because of greater potency of betamethasone in accelerating fetal maturity, surfactant production or antiinflammatory effects than dexamethasone. 18, 19 Furthermore, these effects may arise from betamethasone's preferred pharmacological profile and the method we used for administration, which should produce a more stable and sustained release, a longer half-life and slower clearance due to intramuscularly administered betamethasone rather than intravenous dexamethasone treatment. 27, 28 In the United States, about 5000 to 12 000 newborns develop BPD every year which is associated with an increased risk of cerebral palsy and neurodevelopmental delay. 29, 30 In addition, every 10 days of ventilator therapy is associated with a 20% increase in the incidence of cerebral palsy. 31 Hence, it is generally considered necessary to wean preterm infants from mechanical ventilation and to extubate them as early as possible in an effort to limit the progression of BPD and its associated long-term disabilities. Currently, the treatment of BPD is supportive and largely empirical. Use of the conventional high-dose long-duration (7 days) dexamethasone regimen is efficacious in preventing chronic lung disease, but unsafe with respect to enhanced risk of neurological complications, poor weight gain and rise in blood glucose levels.
7,32-34 Therefore, we sought a therapeutic strategy that was both efficacious in facilitating extubation and reduction in oxygen use and was also safe. Postnatal betamethasone treatment may be one such novel approach to evolving BPD in a subset of only 25% of all ELBWs who are at highest risk using our patient selection strategy.
The major concern against the routine-use dexamethasone in premature infants has been its potential for causing adverse neurological effects, in addition to hypertension, hyperglycemia and a decrease in weight gain. 7, 5 It is important to recognize that the pharmacological effects of glucocorticoids are preparation, dose and exposure dependent.
12,13 Therefore, we chose to use betamethasone at a fourfold lower cortisol-equivalent dose and for half the duration compared to the conventional dexamethasone regimen. We found that delay of weight gain and elevation in blood glucose were less problematic when using betamethasone than dexamethasone whereas effects on clinical lung biology were comparable. Of concern, recent studies have shown a reduction in cerebral blood flow after intravenous betamethasone treatment in both human and sheep newborns; 20, 21 we did not observe any increase in the incidence of PVL in infants treated with betamethasone. In fact, we noted a lower incidence of PVL (0 vs 7%) in infants treated with betamethasone than dexamethasone, although this comparison did not achieve statistical significance. Taken together, our findings suggest that low-dose and shortcourse betamethasone is superior compared to high-dose and longcourse dexamethasone as it had fewer side effects when used for weaning pressure and oxygen during ventilation in early stages of BPD; a larger, properly powered randomized clinical trial will be necessary to confirm this preliminary observations. Our protocol could not distinguish whether the more desirable clinical effects observed in the betamethasone group were due to pharmacological differences in the dose, duration or preparation of glucocorticoid, or a combination of these. However, it is already known that betamethasone is less permeable to the blood-brain barrier than dexamethasone and accordingly, prenatal betamethasone is associated with less risk of cystic periventricular leukomalacia, better neurodevelopmental outcome and reduced risk of hearing impairment compared to prenatal dexamethasone. 16, 35 Moreover, animal and cell culture experiments show that low-dose glucocorticoid is neuroprotective whereas high-dose is neurodegenerative. 15, 36, 37 In a similar but randomized trial using a low-dose dexamethasone protocol (0.15 mg kg À1 per day starting dose with a 10-day tapering course; total exposure: 0.88 mg kg À1 ), 35 ELBW neonates received glucocorticoid and 35 patients received placebo. The hormone-supplemented group showed: (1) facilitated weaning from the ventilator, (2) no significant elevation in blood glucose or blood pressure and (3) reduced postnatal weight gain (50% lower than the control group). Of particular interest to clinicians, the magnitude and timing of changes in PIP, FiO 2 and MAP approximated those achieved in our current report. 38 More importantly, at 2 years corrected postnatal age, the same subjects did not show any difference in adverse long-term sequelae in somatic growth, Bayley scores or the incidence of cerebral palsy. 39 We did not have the opportunity to conduct Bayley testing this group of neonates due to the nature of the retrospective review process.
In another related report, lung compliance in 24 ventilatordependent VLBW neonates also improved on low-dose dexamethasone compared to 23 subjects who received high-dose dexamethasone. 26 These investigators also reported 43% fewer episodes of hyperglycemia and 30% fewer elevated blood pressure events in the low-dose drug exposure group; although the data did not achieve statistical significance due to sample size. Neither of these two reports nor our protocol reduced the incidence of BPD, Figure 2 Time course of changes in weight (top) and blood glucose (bottom) for betamethasone vs dexamethasone groups showing average values of 7 days before, the first 3 days of treatment, days 3 through 7 of treatment and then for 7 days after intervention. There was a significant reduction in weight gain and an elevation in blood glucose in only the dexamethasone group that occurred after just 3 days of glucocorticoid treatment; these adverse metabolic effects were not observed with betamethasone.
(Paired t-test used). *P<0.05.
nevertheless fewer side effects like hyperglycemia, less elevation of blood pressure and no adverse effect on weight gain are each inherent benefits of a low-dose strategy. The major limitation of the present report is that it is a review of practice and not a randomized controlled trial, patient outcomes were simply compared as part of a quality improvement review from two different epochs based on a change in clinical practice. However, the safety (better) and efficacy (same) profiles of betamethasone are encouraging compared to either high-or lowdose dexamethasone. 26, 38 The logical extension of these results and related studies 26, 38 is to compare postnatal betamethasone to reduced-dose dexamethasone and placebo to determine whether it can facilitate weaning from oxygen and mechanical ventilation in premature infants at high risk for BPD. 26, 38 This report provides pilot data on a novel use of postnatal betamethasone to facilitate weaning ELBW premature newborns from mechanical ventilation and provides a rationale for a randomized double-blind clinical trial.
